Tectonic Therapeutic (TECX) Stock Price, News & Analysis

Company Overview

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

Key Stats

• Today's Range: $28.00 to $29.39
• 50-Day Range: $26.87 to $31.17
• 52-Week Range: $14.39 to $36.03
• Volume: 85,510 shs
• Average Volume: 226,308 shs
• Market Capitalization: $547.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $79.40
• Consensus Rating: Buy

Tectonic Therapeutic Stock Analysis - MarketRank™

Tectonic Therapeutic scored higher than 36% of companies evaluated by MarketBeat, and ranked 679th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Buy

Consensus Rating

Tectonic Therapeutic has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Tectonic Therapeutic has a consensus price target of $79.40, representing about 173.8% upside from its current price of $29.00.

Amount of Analyst Coverage

Tectonic Therapeutic has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Tectonic Therapeutic are expected to decrease in the coming year, from ($5.46) to ($5.92) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tectonic Therapeutic is -6.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tectonic Therapeutic is -6.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tectonic Therapeutic has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

23.00% of the float of Tectonic Therapeutic has been sold short.

Short Interest Ratio / Days to Cover

Tectonic Therapeutic has a short interest ratio ("days to cover") of 10.23, which indicates bearish sentiment.

Change versus previous month

Short interest in Tectonic Therapeutic has recently increased by 6.46%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tectonic Therapeutic does not currently pay a dividend.

Dividend Growth

Tectonic Therapeutic does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Tectonic Therapeutic this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for TECX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

1 people have added Tectonic Therapeutic to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Tectonic Therapeutic insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $63,000.00 in company stock.

Percentage Held by Insiders

39.80% of the stock of Tectonic Therapeutic is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

62.63% of the stock of Tectonic Therapeutic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 6/07/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TECX
• Previous Symbol: NASDAQ:TECX
• CIK: 1681087
• Web: www.avrobio.com
• Phone: 617-914-8420
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Tectonic Therapeutic: $79.40
• High Price Target: $101.00
• Low Price Target: $60.00
• Potential Upside/Downside: +173.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.15 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -32.33%
• Return on Assets: -30.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.51
• Quick Ratio: 18.51

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $13.43 per share
• Price / Book: 2.16

Miscellaneous

• Outstanding Shares: 18,870,000
• Free Float: 11,359,000
• Market Cap: $547.23 million
• Optionable: N/A
• Beta: 3.19